Want to see HK:6978 full AI Analyst Report?
Top Page
Immunotech Biopharm Ltd
(6978)
Select Model
Select Model
Rating:40Underperform
Price Target:
HK$0.41
▼(-84.59% Downside)
Action:Reiterated
Date:07/29/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses, sustained cash burn, and negative equity), which materially elevates funding and solvency risk. Technicals add further downside bias as the stock trades far below major moving averages. Valuation provides only limited offset because a negative P/E reflects unprofitability and dividend yield data is unavailable.
Positive Factors
Improving Losses and Cash Burn
The improvement in both net losses and free cash flow during 2025 suggests some cost containment and better operating discipline. While the company remains unprofitable and cash consuming, a sustained reduction in losses could extend financial runway and support progress toward future commercialization.
Negative Factors
No Reported Revenue
The absence of reported revenue over six years indicates that the business has not yet demonstrated commercial monetization. This limits internally generated funding, increases dependence on financing or other resources, and leaves future value tied primarily to successful development and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Losses and Cash Burn
The improvement in both net losses and free cash flow during 2025 suggests some cost containment and better operating discipline. While the company remains unprofitable and cash consuming, a sustained reduction in losses could extend financial runway and support progress toward future commercialization.
Read all positive factors
Immunotech Biopharm Ltd (6978) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$256.26M
Dividend YieldN/A
Average Volume (3M)64.19K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue GrowthN/A
EPS Growth21.82%
CountryHK
Employees189
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.28
Shares Outstanding617,500,800
10 Day Avg. Volume64,500
30 Day Avg. Volume64,187
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)-103.70
Price to Sales (P/S)0.00
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Immunotech Biopharm Ltd Business Overview & Revenue Model
Company Description
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers...
Immunotech Biopharm Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -49.84M | -53.87M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -104.84M | -168.80M | -140.03M | -177.65M | -230.15M | -324.33M |
| Net Income | -168.89M | -230.78M | -186.91M | -334.82M | -318.11M | -354.22M |
Balance Sheet | ||||||
| Total Assets | 479.75M | 603.20M | 564.04M | 846.28M | 879.44M | 1.10B |
| Cash, Cash Equivalents and Short-Term Investments | 65.93M | 154.63M | 57.49M | 176.97M | 79.46M | 353.34M |
| Total Debt | 402.12M | 440.26M | 384.56M | 784.01M | 149.81M | 111.05M |
| Total Liabilities | 519.83M | 569.01M | 580.50M | 675.39M | 373.07M | 274.51M |
| Stockholders Equity | -83.78M | -13.93M | -13.30M | 173.62M | 508.44M | 822.26M |
Cash Flow | ||||||
| Free Cash Flow | -135.97M | -111.92M | -153.81M | -186.17M | -277.49M | -435.89M |
| Operating Cash Flow | -120.53M | -97.29M | -125.74M | -163.63M | -180.92M | -254.65M |
| Investing Cash Flow | -1.20M | -98.07M | 141.10M | -116.60M | 23.38M | -328.21M |
| Financing Cash Flow | 161.74M | 203.20M | -20.59M | 273.92M | -36.06M | -11.00M |
Immunotech Biopharm Ltd Technical Analysis
Negative
2.68
Price Trends
0.39
Positive
0.50
Negative
1.51
Negative
Market Momentum
<0.01
Positive
47.76
Neutral
43.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6978, the sentiment is Negative. The current price of 2.68 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.39, and above the 200-day MA of 1.51, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.76 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6978.
Immunotech Biopharm Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$1.22B | -2.96 | -66.16% | ― | 67.48% | 43.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$2.06B | 20.83 | 48.25% | ― | 88.38% | ― | |
44 Neutral | HK$628.65M | -3.02 | -7.32% | ― | ― | 51.71% | |
42 Neutral | HK$401.13M | -1.92 | -27.54% | ― | 215.14% | 40.49% | |
41 Neutral | HK$835.33M | -7.70 | 85.52% | ― | -55.22% | 57.76% | |
40 Underperform | HK$256.26M | -1.22 | 345.69% | ― | ― | 21.82% |
* Healthcare Sector Average
HK:6978
Immunotech Biopharm Ltd
0.40
-4.27
-91.43%
HK:2137
Brii Biosciences Limited
0.85
-1.18
-58.17%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.77
-1.55
-35.88%
HK:2181
Mabpharm Limited
0.50
-0.18
-26.47%
HK:6628
Transcenta Holding Limited
0.85
-3.10
-78.48%
HK:2496
Wuhan YZY Biopharma Co., Ltd. Class H
2.21
-4.63
-67.72%
Immunotech Biopharm Ltd Corporate Events
Immunotech Biopharm Updates Commercialisation Timeline for Core Cell Therapy EAL®
Sep 30, 2026
Immunotech Biopharm has issued a supplemental announcement to its 2025 annual report, updating investors on the expected commercialisation timeline for its core product EAL®, a non-genetically modified cell therapy for preventing postsurgical...
Immunotech Biopharm Narrows Interim Loss But Net Liabilities Deepen
Aug 21, 2026
Immunotech Biopharm Ltd, a Chinese biopharmaceutical group, concentrates on T cell-based cellular immunotherapies for cancer, anchored by its core product candidate EAL. The firm has developed a proprietary technology platform for EAL production, ...
Immunotech Biopharm Sets August Board Meeting to Approve Interim Results
Aug 11, 2026
Immunotech Biopharm Ltd has scheduled a board meeting for 21 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The planned publication of these interim results will provide investors and other stakeholder...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.